What Are the Requirements for Risk Management Documentation in Overseas Registration of Active Medical Devices?

For overseas registration of active medical devices, the risk management file must not be a simple translation of an ISO 14971 report. It must be locally adapted to the regulatory requirements of the target country. Manufacturers should first determine whether the product falls under that country's medical device regulatory scope, then identify the registration pathway and applicant based on risk classification, and finally assess whether existing NMPA, CE, FDA, ISO 13485, or MDSAP documents can be reused. The risk management file must be closely linked with technical documentation, performance verification, clinical evaluation or clinical evidence, labeling and instructions for use, local agent/authorized representative, and post-market maintenance obligations.

Key Summary

When registering active medical devices overseas, the risk management file is not merely a translated ISO 14971 report. It must be restructured and localized according to the regulatory expectations of each target country. Manufacturers should first confirm whether the product is within the scope of medical device regulation in that country, then determine the registration pathway and applicant based on risk classification, and then evaluate the reusability of existing NMPA, CE, FDA, ISO 13485, or MDSAP documentation. The risk management file must be fully integrated with technical files, performance verification, clinical evaluation or clinical evidence, labeling and instructions for use, local agent/authorized representative requirements, and post-market obligations.

GHWP member countries, Southeast Asia, the Middle East, Latin America, and other markets generally accept core technical files, but localization and adaptation are required. Common pitfalls include incomplete risk analysis scopes, mismatches between the risk management report and electrical safety/EMC standards, failure to consider local use environments, lack of attention to language and regulatory differences across multiple countries, poor linkage with quality system documents, and unclear post-market surveillance and re-evaluation mechanisms. Manufacturers should establish a traceable risk management document structure, ensure clear risk acceptance criteria and a complete evidence chain, and integrate risk management across the entire product life cycle.

For multi-country registration, the core risk management file can be reused, but it must be locally adapted for each country's safety standards, label language, clinical requirements, and authorized representative responsibilities to reduce duplication and the risk of deficiency letters.

Applicable Scenarios and Core Questions

Active medical devices are those powered by electricity or other energy sources, such as patient monitors, ultrasound diagnostic devices, and therapeutic laser equipment. Compared with in vitro diagnostics or passive implants, active devices involve multiple dimensions of risk, including electrical safety, electromagnetic compatibility, radiation protection, and software risk. As a result, regulatory authorities review risk management documentation with particular scrutiny during overseas registration.

A common mistake is treating the risk management file simply as an ISO 14971 report, or assuming that the risk documentation submitted for NMPA registration can be used directly. In reality, different countries and regions have different regulatory frameworks, standard versions, clinical evaluation requirements, and post-market surveillance methods. The risk management file must therefore be reworked and localized.

This article is intended for manufacturers planning overseas registration, regulatory affairs professionals, and quality system managers. It focuses on three questions: What should the risk management file contain? How can you determine whether existing documents can be reused? What are the most frequent mistakes made during preparation?

Registration Determination Logic

Step 1: Confirm Whether the Product Is Within the Target Country's Medical Device Regulatory Scope

Different countries have different definitions and exemptions for medical devices. Some products may not be considered medical devices, or may be classified under other categories. Manufacturers should review the target country's regulations or consult a local agent.

Step 2: Determine Risk Classification and Registration Pathway

Active devices are classified by risk in most countries. Examples include FDA Class II/III in the United States, Class I/IIa/IIb/III in the European Union, Class II/III in China, and risk-based classification in many Southeast Asian countries. The risk classification determines the registration pathway, technical file complexity, and review timeline.

Step 3: Assess the Reusability of Existing Documentation

Manufacturers should inventory existing NMPA registration files, CE technical documentation, FDA 510(k) or PMA files, ISO 13485 quality system documents, MDSAP certificates, and internal reports. Compare each item against the target country's technical file checklist to identify gaps.

Step 4: Confirm the Full Set of Registration Technical Documents

In addition to the risk management file, the technical documentation may include product specifications or performance requirements, design verification and validation records, software life cycle documents, cleaning/disinfection/sterilization validation, stability studies, labeling and instructions for use, and clinical evaluation or clinical data. The risk management file must form a coherent risk chain with these modules.

Step 5: Determine Local Agent, Authorized Representative, and Post-Market Maintenance Arrangements

Most overseas registrations require the foreign manufacturer to appoint a local agent, who takes responsibility for post-market surveillance, vigilance, change control, and other obligations. The post-market surveillance plan in the risk management file must align with these post-registration responsibilities.

Documentation and Evidence

The core basis for the risk management file is usually ISO 14971:2019, the internationally recognized standard for medical device risk management. Most countries accept ISO 14971 as the foundational framework, but require that the report be linked to national safety standards, clinical evaluation, and labeling requirements.

A complete risk management file should include at least: the risk management plan, risk analysis, risk evaluation, risk control measures, evaluation of overall residual risk, the risk management report, and a plan for collection and review of production and post-production information. These elements should form a traceable risk management file.

For active medical devices, special attention should be paid to electrical safety standards (e.g., IEC 60601-1 series), electromagnetic compatibility standards (e.g., IEC 60601-1-2), usability engineering (IEC 62366-1), and software life cycle (IEC 62304). Each essential performance requirement in these standards should serve as a source of hazardous situations in the risk analysis.

For clinical performance, active devices may involve safety, effectiveness, and operator safety. The clinical evaluation section of the risk management file should use clinical data to demonstrate the acceptability of each residual risk in clinical use. Some countries may also require clinical study or clinical trial reports.

Warnings, contraindications, and precautions in labeling and instructions for use must be consistent with the risk control measures in the risk management file. If a risk is identified but not reflected in the labeling, the review authority will consider the risk control to be incomplete.

For multi-country registration, it is recommended to build a master risk management file based on ISO 14971, covering common risks and core control measures. For each target country, add country-specific regulatory requirements, local standard differences, and language translations to create a localized version.

Common Errors

• Incomplete risk analysis scope: Only analyzing normal use and ignoring reasonably foreseeable misuse, failure modes, and the effects of aging.
• Disconnection between the risk management report and safety standards: Failing to map each clause of IEC 60601-1 series standards to the hazard list.
• Ignoring use environment differences: Target country grid voltage, temperature and humidity, emergency scenarios, and operator qualifications are not reflected in the risk analysis.
• Disconnection between risk management and the quality system: Design development, change control, and corrective and preventive action records lack risk management information.
• Inconsistent labeling and instructions for use: Missing warnings and precautions that correspond to the risk management report.
• Vague post-market surveillance content: No explanation of how production post-market information will be collected, reviewed, and used to update the risk management report.
• Unclear local agent responsibilities: Responsibility allocation in the risk management file does not consider local regulatory requirements.
• Insufficient clinical evaluation evidence: For high-risk active devices, insufficient clinical data is provided to support the acceptability of residual risk.

Manufacturer's Preparation Checklist

• Confirm product classification, risk class, and applicable regulations; verify the registration pathway with the target country's regulatory authority or agent.
• Establish or update a risk management procedure aligned with ISO 14971, ensuring that designated risk management personnel and an independent review mechanism are in place.
• Collect and organize existing design inputs, performance verification reports, EMC test reports, electrical safety test reports, and software verification documents.
• Complete the risk management plan and define clear risk acceptability criteria.
• Develop a risk analysis record covering normal use, reasonably foreseeable misuse, and fault conditions.
• Evaluate whether existing risk management documentation is applicable to the target country's standards and requirements.
• Prepare or update clinical evaluation documentation, and plan clinical studies if necessary.
• Establish a local agent/authorized representative relationship and define their responsibilities clearly.
• Develop a labeling and instructions for use revision plan to ensure risk control measures are reflected in the labeling.
• Establish post-market surveillance and vigilance processes to ensure continuous collection of production and post-production information.

AIMEILI Regulatory Interpretation and Business Impact

Based on our extensive experience assisting companies with overseas registration, the most easily misunderstood issue is equating conformity with ISO 14971 to passing overseas regulatory review. The risk management file is not a standalone report; it is an evidence network that cross-validates safety standards, clinical evaluation, and labeling.

In the early stages of a project, two priorities should be addressed: a product technical gap analysis and a feasibility assessment for the target country's registration. Before formally starting registration, determine the product's risk classification and the applicable standard list, and then decide whether design updates or third-party testing are needed.

Among existing documents, NMPA registration files and CE technical documentation are often reusable in terms of basic risk analysis, test data, and quality system documentation. However, pay attention to standard version differences and local regulatory requirements. For example, differences between IEC 60601-1 Edition 3 and Edition 4, or a specific country requiring additional toxicological analysis for certain materials, must not be omitted.

The local agent, certificate control, changes, and renewal are critical. Overseas registration certificates usually belong to the local agent or registrant. If the certificate control rights are not clearly defined in the contract, the certificate may not be transferable when the agent changes. Any post-market changes in design, materials, or labeling must be assessed to determine whether a new registration or change application is required.

For multi-country registration, we strongly recommend using a single master technical file framework, with the risk management file as the main thread linking country-specific technical differences. This approach reduces duplicate work and avoids confusion caused by inconsistent document versions across countries.

Frequently Asked Questions

Must the risk management file be submitted in its original language?

Most countries accept English documents, and some require translations into the local language. Manufacturers should retain the original language version and prepare certified translations.

Can the risk management report in the CE technical file be used directly for US registration?

No, it cannot be fully reused. Although both are based on ISO 14971, the US FDA requires risk management activities to be integrated with specific FDA regulations and applicable standards, with particular emphasis on post-market reporting and risk considerations during premarket review.

What are the special requirements for risk management documentation when registering active devices in Southeast Asia?

Southeast Asian countries (ASEAN) are working toward harmonized medical device directives and common technical documents, but each country still has its own regulations. Companies can refer to the ASEAN Harmonized Technical Requirements, but must still localize for local language, religious, use environment, and other requirements.

Continue Reading

Related articles: Why Does the Registration Timeline for Patient Monitors Get Extended? What Should You Do If Your Quality System Certificate Is Inconsistent for Overseas Registration? For more, please return to the FAQ Center or contact AIMEILI.

Content Author: AIMEILI Regulatory Editorial Department
Professional Review: AIMEILI Medical Device International Registration Project Team
Source Principle: Priority is given to official regulatory agencies, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used only for auxiliary judgment.
Applicability Boundary: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the official requirements of the target country's regulatory authority, testing conclusions, or legal advice.

Published: August 11, 2026, 09:09 | Updated: August 11, 2026, 09:09